DAXXIFY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAXXIFY (DAXXIFY).
DAXXIFY is a botulinum toxin type A formulation that inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, leading to temporary muscle paralysis.
| Metabolism | Botulinum toxins are metabolized via cellular proteolytic degradation; not dependent on hepatic cytochrome P450 enzymes. |
| Excretion | DAXXIFY (daxibotulinumtoxinA-lanm) is a 150 kDa botulinum toxin type A complex. Minimal systemic distribution; excretion is primarily through local metabolism and renal clearance of inactive metabolites. No specific data on % renal vs. fecal; negligible systemic exposure limits traditional excretion quantification. |
| Half-life | The terminal elimination half-life of DAXXIFY is not established in humans due to extremely low systemic concentrations. Based on pharmacokinetic studies, the mean half-life of the 150 kDa toxin in plasma is approximately 0.5–1 day, but clinical effects last much longer due to prolonged local receptor binding. |
| Protein binding | DAXXIFY is a 150 kDa protein; plasma protein binding is negligible due to rapid clearance from circulation. No specific binding proteins identified; minimal systemic exposure precludes precise quantification. |
| Volume of Distribution | Volume of distribution is negligible for DAXXIFY due to local injection and lack of systemic exposure. No Vd value reported; as a large protein, it does not distribute beyond the injection site. |
| Bioavailability | Bioavailability is not applicable for intramuscular injection, as the drug is administered directly to target muscle. Systemic bioavailability is negligible (<1%) due to local retention and metabolism. |
| Onset of Action | Onset of action for glabellar lines: median time to onset is 2–3 days after intramuscular injection, with some patients noting effect within 24 hours. |
| Duration of Action | Duration of action for glabellar lines: median duration is 6–9 months, with some patients maintaining effect up to 12 months. Clinical effect wanes as neural terminals sprout and reestablish function. |
100 Units intramuscularly divided among affected muscles every 12 weeks for glabellar lines; individualized dosing for other indications.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required; renal excretion negligible. |
| Liver impairment | No specific dose adjustment required; hepatic metabolism minimal. |
| Pediatric use | Safety and efficacy not established in patients under 18 years. |
| Geriatric use | No specific dose adjustment; use caution due to potential comorbidities and polypharmacy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DAXXIFY (DAXXIFY).
| Breastfeeding | It is unknown whether daxibotulinumtoxinA is excreted in human milk. Systemic absorption after local intramuscular injection is limited, but the M/P ratio is not established. Caution should be exercised when Daxxify is administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Daxxify and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. |
| Teratogenic Risk | Daxxify (daxibotulinumtoxinA) is classified as a pregnancy category C drug. Animal reproduction studies have not been conducted with daxibotulinumtoxinA. It is not known whether Daxxify can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Daxxify should be given to a pregnant woman only if clearly needed. Botulinum toxins are known to cross the placenta in animal models, and fetal exposure could theoretically cause neuromuscular blockade, leading to developmental abnormalities. Use during the first trimester should be avoided if possible. The risk of systemic effects from local injection is low but not zero. |
■ FDA Black Box Warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT. The effects of botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism, including swallowing and breathing difficulties, which can be life-threatening. There has been no confirmed serious case of distant spread of toxin effect with DAXXIFY at the approved dose.
| Serious Effects |
["Hypersensitivity to any botulinum toxin preparation or any component of the formulation","Infection at the injection site(s)","Intended use for any other indication"]
| Precautions | ["Distant spread of toxin effect","Difficulty swallowing or breathing","Pre-existing neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis)","Eye closure and facial weakness","Injection site reactions","Potential for anaphylaxis and hypersensitivity reactions"] |
Loading safety data…
| Fetal Monitoring | Routine fetal monitoring is not required unless there are signs of systemic botulinum toxicity, which is unlikely with local injections. However, if unintended systemic spread occurs (e.g., dysphagia, respiratory compromise), fetal surveillance (e.g., nonstress test, biophysical profile) should be considered. For pregnant women receiving Daxxify, monitor for signs of excessive muscle weakness, including extraocular muscles, which could affect delivery. No specific maternal or fetal monitoring is mandated beyond standard obstetric care. |
| Fertility Effects | There are no adequate data on the effects of Daxxify on human fertility. Animal fertility studies have not been conducted with daxibotulinumtoxinA. Botulinum toxins, in general, have not been associated with impaired fertility. However, as a neurotoxin that blocks acetylcholine release, theoretical effects on sperm motility or ovarian function are possible but not reported. Patients should be informed of the lack of fertility data. |